Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etentamig
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Etentamig is a multivalent bispecific antibody immunotherapy developed for the treatment of multiple myeloma and light chain (AL) amyloidosis. It targets both B-cell maturation antigen (BCMA), which is expressed on malignant plasma cells, and CD3, found on T-cells. By binding to BCMA on myeloma cells and CD3 on T-cells, etentamig brings these immune cells into close proximity with cancer cells, activating cytotoxic T-cell responses that result in targeted tumor cell killing. The drug is administered intravenously or subcutaneously and leverages technologies such as UniRat and OmniFlic for its antibody engineering. Etentamig was originally developed by TeneoBio/TeneoOne and further advanced by AbbVie; Amgen has also been involved in its development. It has received orphan drug designation for multiple myeloma[1][5][8].
- Brand names
- etentamig
- Other names
- Etentamig-Abbvie/Amgen
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on etentamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etentamig.